Group calls for moratorium on 'dangerous' smart meters
Transfer factor (TF) ... has been used successfully over the past quarter of a century for treating viral, parasitic, and fungal infections, as well as immuno- deficiencies, neoplasias, allergies and autoimmune diseases. Moreover, several observations suggest that it can be utilized for prevention, transferring immunity prior to infection ...Thus, a specific TF to a new influenza virus can be made swiftly and used for prevention as well as for the treatment of infected patients.
“TF reduced significantly the tumour size, and increased CD2+, CD4+, CD8+ and NK cell counts, it also increased the percentage of apoptotic [dying] tumour cells”
“Fifty patients entered this study and received one intra- muscular injection of 2-5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage.”
“These results suggest that, at present, TF may be con- sidered the therapeutic agent of choice in the treatment of herpes simplex type 1 disease.”
“... administration of transfer factor to patients with AIDS resulted in partial immune reconstitution. Further studies are indicated to examine the clinical efficacy of this immune response modifier in the treatment of AIDS.”
“We conclude that transfer factors therapy consider- ably improves the immune status of HIV-infected patients and can be recommended in combating the pathogenesis of the disease. Further studies are needed to determine optimal therapy, the necessity to repeat courses of the treatment and the frequency of therapy needed.”
“Sixty-one patients with leukemia and no immunity to chickenpox were given dialyzable transfer factor or placebo and followed for 12 to 30 months in a double-blind trial designed to examine the clinical efficacy of transfer factor. Sixteen patients in the transfer-factor group and 15 in the placebo group were exposed to varicella zoster, and most of them had a rise in antibody titer. Chickenpox devel- oped in 13 of 15 exposed patients in the placebo group but in only one of 16 in the transfer-factor group.”